|
|
Laura E. Benjamin, Dragan Golijanin, Ahuva Itin, Dov Pode, Eli Keshet
J Clin Invest. 1999;
103(2):159
doi:10.1172/JCI5028
Abstract |
Full text
| PDF

F
eatures that distinguish tumor vasculatures from normal blood vessels are sought to enable the destruction of preformed tumor vessels. We show that blood vessels in both a xenografted tumor and primary human tumors contain a sizable fraction of immature blood vessels that have not yet recruited periendothelial cells. These immature vessels are selectively obliterated as a consequence of vascular endothelial growth factor (VEGF) withdrawal. In a xenografted glioma, the selective vulnerability of immature vessels to VEGF loss was demonstrated by downregulating VEGF transgene expression using a tetracycline-regulated expression system. In human prostate cancer, the constitutive production of VEGF by the glandular epithelium was suppressed as a consequence of androgen-ablation therapy. VEGF loss led, in turn, to selective apoptosis of endothelial cells in vessels devoid of periendothelial cells. These results suggest that the unique dependence on VEGF of blood vessels lacking periendothelial cells can be exploited to reduce an existing tumor vasculature.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(319)
| Title and authors |
Publication |
Year |
Predictive Value of Intratumoral Microvascular Density in Patients with Advanced Non-small Cell Lung Cancer Receiving Chemotherapy Plus Bevacizumab :
Yuan-Yuan Zhao, Cong Xue, Wei Jiang, Hong-Yun Zhao, Yan Huang, Kristin Feenstra, James H. Resau, Chao-Nan Qian, Li Zhang
|
Journal of Thoracic Oncology
|
2012 |
Fibroblast growth factor 2 is a key determinant of vascular sprouting during bovine luteal angiogenesis
K. J. Woad, M. G. Hunter, G. E. Mann, M. Laird, A. J. Hammond, R. S. Robinson
|
Reproduction
|
2012 |
Handbook of Clinical Neurology
Andrew S. Chi, Patrick Y. Wen
|
Neuro-Oncology Vol 104 HCN Series
|
2012 |
Construction of vascularized cardiac tissue from genetically modified mouse embryonic stem cells
Wenjun He, Lingling Ye, Shichong Li, Hong Liu, Benchuan Wu, Qiwei Wang, Xiaobing Fu, Weidong Han, Zhaolie Chen
|
The Journal of Heart and Lung Transplantation
|
2012 |
Vascular endothelial growth factor gene polymorphisms in North Indian patients with end stage renal disease
Swayam Prakash, Narayan Prasad, Raj K. Sharma, Rehan M. Faridi, Suraksha Agrawal
|
Cytokine
|
2012 |
Therapy innovation for the treatment of pancreatic neuroendocrine tumors
Ferdinando Riccardi, Mimma Rizzo, Lucia Festino, Francesca Ambrosio, Carlo Molino, Generoso Uomo, Giacomo Cartenì
|
Expert Opin. Ther. Targets
|
2012 |
A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance
Masakazu Toi, Toshiaki Saeki, Hiroji Iwata, Kenichi Inoue, Yutaka Tokuda, Yasuyuki Sato, Yoshinori Ito, Kenjiro Aogi, Yuichi Takatsuka, Hitoshi Arioka
|
Breast Cancer
|
2012 |
Pericytes on the Tumor Vasculature: Jekyll or Hyde?
Keith D. Barlow, Anne M. Sanders, Shay Soker, Suleyman Ergun, Linda J. Metheny-Barlow
|
Cancer Microenvironment
|
2012 |
Vascular Morphogenesis of Adipose-Derived Stem Cells is Mediated by Heterotypic Cell-Cell Interactions
Daphne L Hutton, Elizabeth A Logsdon, Erika M Moore, Felim Mac Gabhann, Jeffrey Gimble, Warren L Grayson
|
Tissue Engineering Part A
|
2012 |
Multitargeted receptor tyrosine kinase inhibition: An antiangiogenic strategy in non-small cell lung cancer
Mark A. Socinski
|
Cancer Treatment Reviews
|
2011 |
|